Sei Investments Co. Lowers Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Sei Investments Co. lessened its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 8.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,908 shares of the biotechnology company’s stock after selling 866 shares during the quarter. Sei Investments Co.’s holdings in Arrowhead Pharmaceuticals were worth $258,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ARWR. Vanguard Personalized Indexing Management LLC grew its position in Arrowhead Pharmaceuticals by 23.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,751 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 2,405 shares in the last quarter. Edgestream Partners L.P. purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth about $1,401,000. Dimensional Fund Advisors LP lifted its stake in Arrowhead Pharmaceuticals by 139.1% in the second quarter. Dimensional Fund Advisors LP now owns 145,874 shares of the biotechnology company’s stock valued at $3,791,000 after buying an additional 84,867 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 3,333 shares during the period. Finally, Arizona State Retirement System raised its position in Arrowhead Pharmaceuticals by 2.4% in the 2nd quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 821 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 3rd. B. Riley restated a “buy” rating and issued a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.33.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $17.70 on Friday. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $17.05 and a 1-year high of $39.83. The firm has a market capitalization of $2.20 billion, a P/E ratio of -4.16 and a beta of 0.95. The business’s 50-day simple moving average is $21.97 and its 200-day simple moving average is $24.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 152.95%. During the same period last year, the company earned ($0.96) earnings per share. The business’s quarterly revenue was down 100.0% on a year-over-year basis. On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.